treosulfan   Click here for help

GtoPdb Ligand ID: 8281

Synonyms: Trecondi®
Approved drug
treosulfan is an approved drug (UK (1992), EMA (2019))
Compound class: Synthetic organic
Comment: Treosulfan is a DNA alkylating agent.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: treosulfan

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 143.96
Molecular weight 278.01
XLogP -3.29
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(C(COS(=O)(=O)C)O)COS(=O)(=O)C
Isomeric SMILES OC(C(COS(=O)(=O)C)O)COS(=O)(=O)C
InChI InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3
No information available.
Summary of Clinical Use Click here for help
The EMA granted treosulfan orphan drug status to be used as a conditioning treatment prior to haematopoietic progenitor cell transplantation. The FDA has granted orphan drug status for the treatment of ovarian cancer. Four Phase 3 clinical trials assessing treosulfan as a conditioning treatment are ongoing, as are Phase 3 studies for ovarian cancer and Ewing's sarcoma. Full EMA approval was granted in 2019.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
As a DNA alkylating (cross-linking) agent, treosulfan treatment irreversibly interferes with DNA replication, RNA transcription and causes general disruption of nucleic acid function. This action causes cell death.